Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
75 Depression Trials near Fort Lauderdale, FL
Power is an online platform that helps thousands of Depression patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerActive on Power
CYB004 for Generalized Anxiety Disorder
Hollywood, Florida
The purpose of this trial is to examine the preliminary clinical efficacy of CYB004 participants with GAD.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Hypertension, Others
Must Be Taking:Antidepressants, Anxiolytics
36 Participants Needed
Active on Power
Osavampator as an Adjunctive Treatment for Depression
Miami Gardens, Florida
This trial evaluates whether the investigational drug Osavampator (NBI-1065845) helps maintain antidepressant effect by delaying relapse in patients with MDD who had a stable response in the open-label phase.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Psychosis, Others
Must Be Taking:Oral Antidepressants
200 Participants Needed
Active on Power
ABX-002-2001 for Depression
Miami Gardens, Florida
The goal of this clinical trial is to learn if ABX-002 added to an existing antidepressant treatment will benefit depression symptoms in adults with moderate to severe major depressive disorder who have had an inadequate response to their antidepressant. This is a double-blind, placebo-controlled, 2-arm, parallel-group, Phase 2 study, randomized 1:1 (ABX-002: placebo). The study will include the following stages: 1. Screening (approximately 35 days) 2. Treatment period (42 days) 3. Follow-up (2 weeks post treatment)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Epilepsy, Others
Must Be Taking:SSRIs, SNRIs
230 Participants Needed
Azetukalner for Depression
North Miami Beach, Florida
X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult participants who successfully completed an antecedent Phase 3 study of azetukalner in Major Depressive Disorder (MDD).
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Pregnancy, Suicidal Risk, Protocol Deviations, Others
460 Participants Needed
Azetukalner for Depression
Coral Springs, Florida
X-NOVA2 is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study to evaluate the clinical efficacy, safety, and tolerability of azetukalner as a monotherapy in adult participants diagnosed with Major Depressive Disorder (MDD)
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Substance Use, Others
Must Not Be Taking:Antidepressants, Benzodiazepines
450 Participants Needed
BHV-7000 for Depression
Miami Lakes, Florida
This trial is testing a new medication called BHV-7000 to see if it is safe and well-tolerated over several months in people with Major Depressive Disorder. The goal is to help those who suffer from severe depression by potentially offering a new treatment option.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Medical Condition, Non-compliance, Risk To Others
480 Participants Needed
Centanafadine for Depression
North Miami, Florida
This is a phase 2, multicenter, randomized, double-blind, placebo-controlled, parallel-arm trial to assess the efficacy, safety, and tolerability of centanafadine once-daily (QD) extended-release (XR) capsules for the treatment of adult subjects diagnosed with Major Depressive Disorder (MDD).
The trial will evaluate the efficacy and safety of centanafadine QD XR capsules as monotherapy or as adjunct to the selective serotonin reuptake inhibitor (SSRI), escitalopram.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, PTSD, Others
Must Be Taking:SSRIs
336 Participants Needed
Lumateperone for Pediatric Bipolar Depression
Miami Gardens, Florida
This is a multicenter, randomized, double-blind, placebo-controlled study in pediatric patients who are experiencing major depressive episodes (MDEs) associated with a primary diagnosis of bipolar I or bipolar II disorder as confirmed by Kiddie Schedule for Affective Disorders and Schizophrenia for School-Age Children-Present and Lifetime Version (K-SADS-PL), according to criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM 5).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:10 - 17
Key Eligibility Criteria
Disqualifiers:Intellectual Disability, Suicidal Risk, Others
384 Participants Needed
VNS for Bipolar Depression
Boca Raton, Florida
This trial is testing whether VNS Therapy, which sends electrical impulses to the vagus nerve, can reduce depression symptoms in patients who haven't responded to other treatments. The study will observe the effects of VNS therapy over a year. Vagus nerve stimulation (VNS) is a recognized treatment for severe treatment-resistant depression and has shown promising results.
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Psychotic Disorders, Schizophrenia, Bipolar, Dementia, Others
6800 Participants Needed
Aticaprant + Antidepressant for Depression
North Miami Beach, Florida
The purpose of this study is to assess how well aticaprant works compared to placebo when given in addition to antidepressant therapy (selective serotonin reuptake inhibitor \[SSRI\] or serotonin-norepinephrine reuptake inhibitor \[SNRI\]) in preventing return of depression symptoms in participants with major depressive disorder who experience a loss of interest and pleasure and who achieve a stable response after treatment with adjunctive aticaprant.
Stay on current meds
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 3
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Not Listed
660 Participants Needed
Active on Power
SEP-363856 for Major Depressive Disorder
Miami, Florida
A Phase 2/3 Trial is designed to evaluate SEP-363856 as Adjunctive Therapy in the Treatment of Adults With Major Depressive Disorder
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, PTSD, Others
900 Participants Needed
Milsaperidone for Depression
Miami, Florida
The purpose of this study is to determine the efficacy and safety of milsaperidone compared to placebo as adjunctive therapy in patients with Major Depressive Disorder
Stay on current meds
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Other Psychiatric Diagnoses, Others
Must Be Taking:Antidepressants
500 Participants Needed
Solriamfetol for Depression
Hialeah, Florida
This trial is testing solriamfetol, a medication that may help improve symptoms of depression. It targets adults with major depressive disorder (MDD) who do not have psychotic features. Solriamfetol works by affecting brain chemicals involved in mood regulation, potentially helping to improve mood and reduce depression symptoms.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Prior Solriamfetol Exposure, Others
300 Participants Needed
Lumateperone for Major Depressive Disorder
Hialeah, Florida
This trial is testing lumateperone, a medication that may help people with depression who haven't improved with other treatments. The study includes patients diagnosed with Major Depressive Disorder who haven't responded well to their current antidepressants. Lumateperone works by balancing brain chemicals that affect mood, potentially improving depressive symptoms.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Schizophrenia, Bipolar, Anxiety, Others
Must Be Taking:Antidepressants
470 Participants Needed
AXS-05 for Depression
Miami, Florida
This trial is testing AXS-05, a new medication, to see if it can prevent depression from returning in people who have already improved with it. The study focuses on those with major depressive disorder and aims to maintain their balanced brain chemicals to keep them feeling better. AXS-05 (a combination of dextromethorphan and bupropion) has shown positive results in previous trials for major depressive disorder.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Other AXS-05 Studies, Others
Must Not Be Taking:Auvelity
350 Participants Needed
Stem Cell Therapy for Alcoholism and Depression
Miami, Florida
The purpose of this study is to look at the safety of a study treatment with stem cells in Alcohol Use Disorder And Major Depression (AUD-MD) subjects.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Bipolar, Schizophrenia, Autoimmune, Others
Must Not Be Taking:Psychotropics, Steroids, NSAIDs, Others
80 Participants Needed
Zelquistinel for Depression
Miami, Florida
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are:
Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)?
What medical problems are observed in participants who take GATE-251?
Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.
Trial Details
Trial Status:Not Yet Recruiting
Trial Phase:Phase 2
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Bipolar, OCD, PTSD, Others
Must Not Be Taking:Antidepressants, Antipsychotics, Benzodiazepines, Others
164 Participants Needed
Ropanicant for Depression
Miami, Florida
The primary objective is to evaluate the efficacy of Ropanicant at two different dosage levels compared to placebo in patients with Major Depressive Disorder (MDD).
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 65
Key Eligibility Criteria
Disqualifiers:Treatment-resistant Depression, Pregnancy, Heart Rate Issues, Others
195 Participants Needed
Zelquistinel for Depression
Miami, Florida
The goal of this clinical trial is to learn if GATE-251 works to treat depression in adults. It will also learn about the safety of GATE-251. The main questions it aims to answer are:
Does GATE-251 reduce depression scores in participants compared to participants who take a placebo (a look-alike tablet that contains no GATE-251)?
What medical problems are observed in participants who take GATE-251?
Participants will take one tablet of GATE-251 or placebo every week for 6 weeks. Participants will visit the clinic every week of the 6 week period to have the severity of their depression evaluated.
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:18 - 64
Key Eligibility Criteria
Disqualifiers:Bipolar, Psychotic Disorders, Substance Abuse, Others
Must Not Be Taking:Antidepressants, Antipsychotics, Mood Stabilizers, Others
164 Participants Needed
Mobile App for Stress and Depression During Pregnancy
Miami, Florida
The Cocooned Moms Study is a pre- and post-design study primarily aimed at reducing stress, depressive symptoms, and blood pressure among expectant Black women by providing them with free access to the InovCares mobile app. InovCares is a culturally-sensitive telehealth platform designed for community-based care coordination in maternal care. It also offers a culturally tailored maternal mental health program, which provides access to resources addressing social determinants of health, cognitive behavioral therapy (CBT), interpersonal therapy, and compassion-focused therapy (CFT), along with peer-to-peer support and gamification. The study will evaluate the impact of these interventions on reported stress levels, depressive symptoms, sleep quality, and blood pressure (BP) among Black pregnant women.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Psychosis, Non-English, Non-pregnant, Others
384 Participants Needed
Why Other Patients Applied
"I have struggled my entire life with depression. I feel like it took away half my life because I've been unable to truly feel the good times and people around me, like I'm numb. I would like to take part to see if it might help me, but I would also like to help others by doing this trial if I am accepted. I would love to enjoy life and truly feel the happy experiences that might come my way rather than observe them without feeling."
EW
Depression PatientAge: 45
"Dealt with treatment-resistant depression for pretty much my entire life. I would be eternally grateful for something that actually worked for once. I'd just like to feel normal. "
CM
Depression PatientAge: 55
"Tried Lexapro, Wellbutrin and another (forget which). Surgical accident destroyed my mental nerve and left me in chronic pain, depression, and anxiety. That was 15 years ago. Disabled and retired. I'm tired of this."
IH
Depression PatientAge: 73
"I've experienced drug resistant MDD for 2 decades. I have had no success with CBT and medication, nor either alone. I had success once with TMS, about 5 sessions, in 2014. I have not had TMS since then."
YB
Depression PatientAge: 58
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
Cannabis Use for Depression in Adolescents
Miami, Florida
The goal of this study is to investigate the effects of cannabis on brain function among adolescents with depression.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:14 - 20
Key Eligibility Criteria
Disqualifiers:MRI Contraindications, Pregnancy, Neurological Illnesses, Low IQ, SUD, Others
Must Not Be Taking:Psychotropics, Stimulants
280 Participants Needed
Cognitive Behavioral Therapy for Depression in HIV
Miami, Florida
The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the gut), immune system, and the brain functioning in people living with HIV.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Untreated Mental Illness, Pregnancy, Others
Must Be Taking:Antiretrovirals
150 Participants Needed
The purpose of this study is to look at the best ways to prevent anxiety and depression in older Latino adults who are at risk for developing anxiety and depression. Participants will be randomized to either a health promotion intervention or a healthy lifestyles education program.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Unphased
Age:60+
Key Eligibility Criteria
Disqualifiers:MDD, GAD, Substance Abuse, Others
Must Not Be Taking:Steroids, Anti-inflammatories, Antidepressants, Others
240 Participants Needed
eHealth Familias Unidas for Depression and Anxiety
Miami, Florida
The goal of this study is to evaluate in an effectiveness-implementation type I hybrid trial, an enhanced version of eHealth Familias Unidas for reducing depressive, anxious symptoms and suicide behavior in Hispanic youth. The study will use a randomized rollout design with 18 pediatric primary care clinics in the South Florida area.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:12 - 16
Key Eligibility Criteria
Disqualifiers:Moving Out Of South Florida
468 Participants Needed
This trial is studying how using cannabis and having depression together affect young people living with HIV. Researchers believe that these conditions combined might make it harder for them to feel pleasure and could increase their sensitivity to pain. The goal is to see if these effects lead to worse health outcomes over time.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:18 - 59
Key Eligibility Criteria
Disqualifiers:Pregnancy, Severe Illness, CNS Disease, Others
Must Not Be Taking:Psychotropics, Cocaine
280 Participants Needed
Mobile App Support for Post-Traumatic Stress Disorder
Miami, Florida
This study focuses on the mental health challenges faced by the World Trade Center's (WTC) General Responders due to the severe psychological trauma from the WTC collapse. PTSD and depression are among the top mental health conditions affecting these responders. Many members of the WTC Health Program (WTCHP) have relocated to Florida, making up nearly six percent of the cohort. Furthermore, many identify as Latinx, highlighting the need for services in their preferred language to promote health equity. Studies have shown that remotely-delivered, clinician-supported applications (apps) can reduce adverse MH symptoms.
PTSD Coach was developed by the Veteran's Administration as a self-managed mobile app and is available at no cost for Android and Apple devices. The primary focus of PTSD Coach is on managing PTSD symptoms. The app offers coping tools such as relaxation exercises and calming self-talk and effective sleep hygiene practices when needed. A recent review evaluated the self-managed PTSD Coach app and found it to be feasible, acceptable, and effective in reducing PTSD symptoms.
Clinician-Supported PTSD Coach was developed as a brief intervention for Veterans who were unlikely to use a mobile app on their own. Clinician Supported PTSD Coach combines PTSD Coach mobile app with four remotely-delivered 20-30 minute sessions over 8 weeks with a clinician. Studies with Veterans have reported significant reductions in PTSD and depression symptoms, treatment satisfaction and more treatment sessions attended, when compared with typical mental health care. While promising, none of these studies included WTC General Responders or focused on Latinx populations.
Given the promise of these interventions, and the need to provide support for geographically dispersed General Responders in Florida, this study aims to evaluate the feasibility, acceptability, and effectiveness of Clinician Supported PTSD Coach in reducing symptoms of PTSD, depression, anxiety, and sleep disturbances among English and Spanish-speaking WTC General Responders. Participants will be randomly assigned to one of three conditions:
1. Clinician-Supported PTSD Coach
2. Self-Managed PTSD Coach
3. Waitlist Control (no treatment until after follow-up)
Assessments will be conducted at the end of treatment (8 weeks) and at follow-up (12 weeks). The study will measure reductions in PTSD, depression, anxiety, and sleep disturbances at 8 weeks and 12 weeks. It is expected that both Clinician Supported PTSD Coach and Self-Managed PTSD Coach will reduce symptoms, with Clinician Supported PTSD Coach showing larger reductions. In addition, to assess feasibility and acceptability, the study will assess engagement, satisfaction, and barriers in both PTSD Coach app conditions.
This project aims to fill a significant gap in evidence-based mental health treatments for WTC General Responders. It responds to the WTCHP Scientific Technical Advisory Committee's call for more research on mental health interventions and addresses the critical shortage of rigorously tested app-based remote interventions for dispersed General Responders with PTSD. The study also focuses on Spanish-speaking Latinx General Responders, a group that has not been specifically targeted in previous interventions. The study's findings could lead to the development of readily deployable interventions nationally to meet the mental health needs of WTC responders and survivors, providing a valuable resource for treatment researchers and health care providers.
No Placebo Group
Trial Details
Trial Status:Enrolling By Invitation
Trial Phase:Unphased
Key Eligibility Criteria
Disqualifiers:Suicidal Ideation, Severe Alcohol Use, Illicit Drugs, Neurologic Conditions, Others
120 Participants Needed
Tai Chi/Qigong for Depression in People Living with HIV
Miami, Florida
The goal of this randomized clinical trial is to learn if tai chi/qigong decreases depressive symptoms among older people living with HIV compared to a health education class. The main questions it aims to answer are:
Does tai chi/qigong reduce depressive symptoms among older people living with HIV more than a health education class? What are the behavioral, psychological, and biological mechanisms in which tai chi/qigong affects depressive symptoms? Does tai chi/qigong affect depressive symptoms among older people living with HIV differently for men compared to women?
Researchers will compare a 12-week, twice a week remotely delivered tai chi/qigong intervention to a health education class of the same duration to determine if it improves depressive symptoms among older people living with HIV.
Participants will:
Attend either a tai chi/qigong class twice a week for 12 weeks or a health education class of the same duration delivered via Zoom. Each class will be 45-60 minutes in length.
Participate in 3 separate interviewer-administered interviews: at the time of enrollment, 3 months after the last class, and 9 months after the last class.
Keep a tracking log of their home practice of tai chi/qigong (only participants in the intervention group).
Use a biosensor (an earlobe sensor or chest strap) to measure their heart variability.
Go to their local lab (e.g., Quest or Labcorp) for blood draw at the time of enrollment and at 9 month post intervention (this will only be a subset of participants).
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Age:50 - 75
Key Eligibility Criteria
Disqualifiers:High Suicide Risk, Recent Mental Health Study, Excessive Exercise
326 Participants Needed
Valbenazine for Tardive Dyskinesia
Miami, Florida
This study will evaluate the efficacy of valbenazine on clinician- and patient-reported outcomes in participants with TD while receiving or after stopping a VMAT2 inhibitor.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 4
Key Eligibility Criteria
Disqualifiers:Parkinsonism, Substance Use Disorder, Others
Must Be Taking:VMAT2 Inhibitors
50 Participants Needed
Online Intervention for HIV/AIDS
Miami, Florida
The purpose of this research is to test ORCHID (Optimizing Resilience \& Coping with HIV through Internet Delivery), a skills-building intervention that improves mental health status for persons with HIV, who are at-risk for falling out of care.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Unphased
Sex:Female
Key Eligibility Criteria
Disqualifiers:Under 18, Cognitive Impairment, Schizophrenia, Others
30 Participants Needed
Seltorexant for Depression
North Bay Village, Florida
This trial is testing seltorexant to see if it can help people with depression and insomnia who haven't improved with their current antidepressants. Seltorexant aims to improve mood and sleep by acting on certain brain receptors.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Key Eligibility Criteria
Disqualifiers:Not Listed
752 Participants Needed
Know someone looking for new options?
Spread the word